Scholarlink

Background <p>The emergence of real-time molecular monitoring has challenged traditional oncology paradigms, where radiologic progression has historically represented the primary trigger for therapeutic intervention. The SERENA-6 clinical trial introduced a novel treatment approach by adapting therapy based on ctDNA-detected molecular progression before radiologic progression in patients with HR-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations. The trial has prompted important discussion regarding the integration of molecular biomarkers into treatment decision-making and regulatory frameworks.</p> Methods <p>We reviewed the ODAC deliberations, regulatory discussions, published data, and expert perspectives surrounding SERENA-6 to examine the clinical, scientific, and regulatory implications of ctDNA-guided treatment adaptation and molecularly adaptive trial designs.</p> Results <p>The SERENA-6 trial demonstrated significant improvements in progression-free survival, durable disease control, and quality of life outcomes. However, important considerations remain regarding the optimal timing of treatment adaptation, evidence required to support molecularly guided switching strategies, interpretation of crossover and survival outcomes, and the regulatory evaluation of adaptive precision oncology trials.</p> Conclusion <p>As oncology transitions toward biologically driven treatment strategies, new clinical and regulatory frameworks are needed to define when molecular alterations should become actionable. SERENA-6 challenges the traditional reliance on radiologic progression as the sole trigger for therapeutic intervention and provides important lessons for the future development and evaluation of molecularly adaptive precision oncology strategies beyond breast cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

SERENA-6 and the regulatory limits of radiologic progression in modern oncology

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月8日

查看全文
  • Saeed Rafii,
  • Humaid O Al-Shamsi,
  • Adam Brufsky

摘要

Background

The emergence of real-time molecular monitoring has challenged traditional oncology paradigms, where radiologic progression has historically represented the primary trigger for therapeutic intervention. The SERENA-6 clinical trial introduced a novel treatment approach by adapting therapy based on ctDNA-detected molecular progression before radiologic progression in patients with HR-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations. The trial has prompted important discussion regarding the integration of molecular biomarkers into treatment decision-making and regulatory frameworks.

Methods

We reviewed the ODAC deliberations, regulatory discussions, published data, and expert perspectives surrounding SERENA-6 to examine the clinical, scientific, and regulatory implications of ctDNA-guided treatment adaptation and molecularly adaptive trial designs.

Results

The SERENA-6 trial demonstrated significant improvements in progression-free survival, durable disease control, and quality of life outcomes. However, important considerations remain regarding the optimal timing of treatment adaptation, evidence required to support molecularly guided switching strategies, interpretation of crossover and survival outcomes, and the regulatory evaluation of adaptive precision oncology trials.

Conclusion

As oncology transitions toward biologically driven treatment strategies, new clinical and regulatory frameworks are needed to define when molecular alterations should become actionable. SERENA-6 challenges the traditional reliance on radiologic progression as the sole trigger for therapeutic intervention and provides important lessons for the future development and evaluation of molecularly adaptive precision oncology strategies beyond breast cancer.